small molecule

LUBIPROSTONE

LUBIPROSTONE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameLUBIPROSTONE
Active ingredientLUBIPROSTONE
Strength24MCG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2021
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.